Skip to main content
SpringerLink
Log in

Approach to Pain in Patients with Central Nervous System Metastases

  • Chapter
  • First Online:
Central Nervous System Metastases

  • 626 Accesses

Abstract

Central nervous system (CNS) metastasis is the condition by which a primary malignancy may spread to structures such as the brain, spinal cord, meninges, or cerebrospinal fluid. A multidisciplinary approach is necessary to care for patients with CNS metastases, with treatment of the oncologic condition to include radiation (external beam radiotherapy, brachytherapy, and stereotactic radiosurgery), systemic therapies (chemotherapy, immunotherapy, targeted therapy, and hormone therapy), intrathecal therapies, and surgery. The management of pain related to CNS metastases requires an understanding not only of the pathophysiology of the underlying malignant process but also of the pathophysiology of pain. Furthermore, clinician knowledge about the available pharmacologic agents and interventional modalities is necessary to provide a comprehensive approach to cancer pain management in patients with CNS metastases. The main foci of this chapter are to explain pain processing and to describe the various classes of pharmacologic agents used to treat the different types of pain, with emphasis on neuropathic-type pain, associated with CNS metastases. Interventional modalities to manage pain from CNS metastases are described in a separate chapter in this book.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kannan TR, Saxena A, Bhatnagar S, Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manag. 2002;23(1):60–5.

    Article  CAS  Google Scholar 

  2. Mercadante S, Arcuri E, Tirelli W, Villari P, Casuccio A. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumori. 2002;88(3):239–42.

    Article  CAS  PubMed  Google Scholar 

  3. Dou Z, Jiang Z, Zhong J. Efficacy and safety of pregabalin in patients with neuropathic cancer pain undergoing morphine therapy. Asia Pac J Clin Oncol. 2017;13(2):e57–64.

    Article  PubMed  Google Scholar 

  4. Arbaiza D, Vidal O. Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study. Clin Drug Investig. 2007;27(1):75–83.

    Article  CAS  PubMed  Google Scholar 

  5. Mannino R, Coyne P, Swainey C, Hansen LA, Lyckholm L. Methadone for cancer-related neuropathic pain: a review of the literature. J Opioid Manag. 2006;2(5):269–76.

    Article  PubMed  Google Scholar 

  6. Leppert W, Kowalski G. Methadone as an additional opioid for a cancer patient with severe neuropathic and bone pain not responsive to other opioids and adjuvant analgesics. J Palliat Care. 2013;29(2):119–21.

    Article  PubMed  Google Scholar 

  7. Makin MK, Ellershaw JE. Substitution of another opioid for morphine. Methadone can be used to manage neuropathic pain related to cancer. BMJ. 1998;317(7150):81.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Sugiyama Y, Sakamoto N, Ohsawa M, Onizuka M, Ishida K, Murata Y, et al. A retrospective study on the effectiveness of switching to oral methadone for relieving severe cancer-related neuropathic pain and limiting adjuvant analgesic use in Japan. J Palliat Med. 2016;19(10):1051–9.

    Article  PubMed  Google Scholar 

  9. Jonkman K, van de Donk T, Dahan A. Ketamine for cancer pain: what is the evidence? Curr Opin Support Palliat Care. 2017;11(2):88–92.

    Article  PubMed  Google Scholar 

  10. Mercadante S, Lodi F, Sapio M, Calligara M, Serretta R. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manag. 1995;10(7):564–8.

    Article  CAS  Google Scholar 

  11. Waldfogel JM, Nesbit S, Cohen SP, Dy SM. Successful treatment of opioid-refractory cancer pain with short-course, low-dose ketamine. J Pain Palliat Care Pharmacother. 2016;30(4):294–7.

    Article  PubMed  Google Scholar 

  12. Loveday BA, Sindt J. Ketamine protocol for palliative care in cancer patients with refractory pain. J Adv Pract Oncol. 2015;6(6):555–61.

    PubMed  PubMed Central  Google Scholar 

  13. Okamoto Y, Tsuneto S, Tanimukai H, Matsuda Y, Ohno Y, Tsugane M, et al. Can gradual dose titration of ketamine for management of neuropathic pain prevent psychotomimetic effects in patients with advanced cancer? Am J Hosp Palliat Care. 2013;30(5):450–4.

    Article  PubMed  Google Scholar 

  14. Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend. 2018;189:37–41.

    Article  PubMed  Google Scholar 

  15. Lambdin BH, Davis CS, Wheeler E, Tueller S, Kral AH. Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States. Drug Alcohol Depend. 2018;188:370–6.

    Article  PubMed  Google Scholar 

  16. Davis CS, Southwell JK, Niehaus VR, Walley AY, Dailey MW. Emergency medical services naloxone access: a national systematic legal review. Acad Emerg Med. 2014;21(10):1173–7.

    Article  PubMed  Google Scholar 

  17. Davis CS, Burris S, Beletsky L, Binswanger IMMM. Co-prescribing naloxone does not increase liability risk. Subst Abus. 2016;37(4):498–500.

    Article  PubMed  PubMed Central  Google Scholar 

  18. McCabe SE, Cranford JA, West BT. Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys. Addict Behav. 2008;33(10):1297–305.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Meyer R, Patel AM, Rattana SK, Quock TP, Mody SH. Prescription opioid abuse: a literature review of the clinical and economic burden in the United States. Popul Health Manag. 2014;17(6):372–87.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Moeller KE, Kissack JC, Atayee RS, Lee KC. Clinical interpretation of urine drug tests: what clinicians need to know about urine drug screens. Mayo Clin Proc. 2017;92(5):774–96.

    Article  CAS  PubMed  Google Scholar 

  21. Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83(1):66–76.

    Article  CAS  PubMed  Google Scholar 

  22. Ross JR, Goller K, Hardy J, Riley J, Broadley K, A’Hern R, et al. Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. J Palliat Med. 2005;8(6):1118–26.

    Article  CAS  PubMed  Google Scholar 

  23. Caraceni A, Zecca E, Bonezzi C, Arcuri E, Yaya Tur R, Maltoni M, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22(14):2909–17.

    Article  CAS  PubMed  Google Scholar 

  24. Arai YC, Matsubara T, Shimo K, Suetomi K, Nishihara M, Ushida T, et al. Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. J Anesth. 2010;24(3):407–10.

    Article  PubMed  Google Scholar 

  25. Raptis E, Vadalouca A, Stavropoulou E, Argyra E, Melemeni A, Siafaka I. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. Pain Pract. 2014;14(1):32–42.

    Article  PubMed  Google Scholar 

  26. Manas A, Ciria JP, Fernandez MC, Gonzalvez ML, Morillo V, Perez M, et al. Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health. Clin Transl Oncol. 2011;13(9):656–63.

    Article  PubMed  Google Scholar 

  27. Di Stefano G, La Cesa S, Truini A, Cruccu G. Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. J Headache Pain. 2014;15:34.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Razazian N, Baziyar M, Moradian N, Afshari D, Bostani A, Mahmoodi M. Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial. Neurosciences (Riyadh). 2014;19(3):192–8.

    Google Scholar 

  29. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain. 2014;155(11):2263–73.

    Article  CAS  PubMed  Google Scholar 

  30. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hirayama Y, Ishitani K, Sato Y, Iyama S, Takada K, Murase K, et al. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol. 2015;20(5):866–71.

    Article  CAS  PubMed  Google Scholar 

  32. Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, et al. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer. 2011;117(24):5469–75.

    Article  CAS  PubMed  Google Scholar 

  33. Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, et al. Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol. 2018;36(4):326–32.

    Article  CAS  PubMed  Google Scholar 

  34. Matsuoka H, Makimura C, Koyama A, Otsuka M, Okamoto W, Fujisaka Y, et al. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. Anticancer Res. 2012;32(5):1805–9.

    CAS  PubMed  Google Scholar 

  35. Matsuoka H, Ishiki H, Iwase S, Koyama A, Kawaguchi T, Kizawa Y, et al. Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. BMJ Open. 2017;7(8):e017280.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Banerjee M, Pal S, Bhattacharya B, Ghosh B, Mondal S, Basu J. A comparative study of efficacy and safety of gabapentin versus amitriptyline as coanalgesics in patients receiving opioid analgesics for neuropathic pain in malignancy. Indian J Pharmacol. 2013;45(4):334–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care. 2012;29(3):177–82.

    Article  PubMed  Google Scholar 

  38. Lopez RE. Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5% patches. A radiation and oncology department experience. Support Care Cancer. 2013;21(5):1329–34.

    Article  Google Scholar 

  39. Fleming JA, O’Connor BD. Use of lidocaine patches for neuropathic pain in a comprehensive cancer Centre. Pain Res Manag. 2009;14(5):381–8.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Kern KU, Nalamachu S, Brasseur L, Zakrzewska JM. Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain? J Pain Res. 2013;6:261–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Crawford P, Xu Y. Topical capsaicin for treatment of chronic neuropathic pain in adults. Am Fam Physician. 2017;96(11):Online.

    Google Scholar 

  42. Schumacher M, Pasvankas G. Topical capsaicin formulations in the management of neuropathic pain. Prog Drug Res. 2014;68:105–28.

    CAS  PubMed  Google Scholar 

  43. Ellison N, Loprinzi CL, Kugler J, Hatfield AK, Miser A, Sloan JA, et al. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol. 1997;15(8):2974–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pain Medicine, UT MD Anderson Cancer Center, Houston, TX, USA

    Thomas Chai, Jennifer Erian, Larry C. Driver & Dhanalakshmi Koyyalagunta

  2. Department of Physical Medicine & Rehabilitation, Baylor College of Medicine, Houston, TX, USA

    Mihir Joshi

Authors
  1. Thomas Chai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Erian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mihir Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Larry C. Driver
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dhanalakshmi Koyyalagunta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Chai .

Editor information

Editors and Affiliations

  1. Department of Neurological Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medicine, Director - Brain Metastases Program, New York, NY, USA

    Rohan Ramakrishna

  2. Department of Neurology, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Rajiv S. Magge

  3. Department of Neurological Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Ali A. Baaj

  4. Department of Radiation Oncology, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Jonathan P.S. Knisely

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chai, T., Erian, J., Joshi, M., Driver, L.C., Koyyalagunta, D. (2020). Approach to Pain in Patients with Central Nervous System Metastases. In: Ramakrishna, R., Magge, R., Baaj, A., Knisely, J. (eds) Central Nervous System Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-42958-4_51

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-42958-4_51

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-42957-7

  • Online ISBN: 978-3-030-42958-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation